Search details
1.
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
N Engl J Med
; 388(22): 2058-2070, 2023 Jun 01.
Article
in English
| MEDLINE | ID: mdl-37256976
2.
Effect of baseline oestradiol serum concentration on the efficacy of anastrozole for preventing breast cancer in postmenopausal women at high risk: a case-control study of the IBIS-II prevention trial.
Lancet Oncol
; 25(1): 108-116, 2024 Jan.
Article
in English
| MEDLINE | ID: mdl-38070530
3.
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
N Engl J Med
; 384(16): 1529-1541, 2021 04 22.
Article
in English
| MEDLINE | ID: mdl-33882206
4.
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
N Engl J Med
; 384(25): 2394-2405, 2021 06 24.
Article
in English
| MEDLINE | ID: mdl-34081848
5.
Impact of Imaging-Guided Localization on Performance of Tailored Axillary Surgery in Patients with Clinically Node-Positive Breast Cancer: Prospective Cohort Study Within TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101).
Ann Surg Oncol
; 31(1): 344-355, 2024 Jan.
Article
in English
| MEDLINE | ID: mdl-37903951
6.
Radiotherapy statements of the 18th St. Gallen International Breast Cancer Consensus Conference-a German expert perspective.
Strahlenther Onkol
; 2024 Feb 23.
Article
in English
| MEDLINE | ID: mdl-38393398
7.
The effect of denosumab on disseminated tumor cells (DTCs) of breast cancer patients with neoadjuvant treatment: a GeparX translational substudy.
Breast Cancer Res
; 25(1): 32, 2023 03 28.
Article
in English
| MEDLINE | ID: mdl-36978142
8.
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
N Engl J Med
; 382(7): 597-609, 2020 02 13.
Article
in English
| MEDLINE | ID: mdl-31825569
9.
Trends in use of neoadjuvant systemic therapy in patients with clinically node-positive breast cancer in Europe: prospective TAXIS study (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101).
Breast Cancer Res Treat
; 201(2): 215-225, 2023 Sep.
Article
in English
| MEDLINE | ID: mdl-37355526
10.
Characterization of Hormone Receptor and HER2 Status in Breast Cancer Using Mass Spectrometry Imaging.
Int J Mol Sci
; 24(3)2023 Feb 02.
Article
in English
| MEDLINE | ID: mdl-36769215
11.
mdm2 gene amplification is associated with luminal breast cancer progression in humanized PDX mice and a worse outcome of estrogen receptor positive disease.
Int J Cancer
; 150(8): 1357-1372, 2022 04 15.
Article
in English
| MEDLINE | ID: mdl-34927257
12.
Breast cancer.
Lancet
; 397(10286): 1750-1769, 2021 05 08.
Article
in English
| MEDLINE | ID: mdl-33812473
13.
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.
N Engl J Med
; 380(20): 1929-1940, 2019 05 16.
Article
in English
| MEDLINE | ID: mdl-31091374
14.
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
N Engl J Med
; 380(7): 617-628, 2019 02 14.
Article
in English
| MEDLINE | ID: mdl-30516102
15.
EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy.
BMC Cancer
; 22(1): 1040, 2022 Oct 05.
Article
in English
| MEDLINE | ID: mdl-36195836
16.
Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon.
Future Oncol
; 18(28): 3199-3215, 2022 Sep.
Article
in English
| MEDLINE | ID: mdl-36069628
17.
Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials.
Lancet Oncol
; 22(8): 1151-1161, 2021 08.
Article
in English
| MEDLINE | ID: mdl-34252375
18.
Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox.
Lancet Oncol
; 22(1): e18-e28, 2021 01.
Article
in English
| MEDLINE | ID: mdl-33387500
19.
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study.
Lancet Oncol
; 22(2): 212-222, 2021 02.
Article
in English
| MEDLINE | ID: mdl-33460574
20.
Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial.
Lancet
; 395(10218): 117-122, 2020 01 11.
Article
in English
| MEDLINE | ID: mdl-31839281